<DOC>
	<DOCNO>NCT00003765</DOCNO>
	<brief_summary>Phase I trial study effectiveness O6-benzylguanine carmustine treat child refractory CNS tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>O6-benzylguanine Carmustine Treating Children With Refractory CNS Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity carmustine administer O6-benzylguanine child refractory primary CNS tumor . II . Determine safe tolerable dose carmustine administer O6-benzylguanine use phase II study . III . Determine pharmacokinetics O6-benzylguanine metabolite , O6-benzyl-8-oxoguanine , patient . IV . Seek preliminary evidence antitumor activity regimen patient . V. Evaluate acute chronic toxicity , describe cumulative toxicity , patient treat multiple course regimen . OUTLINE : This dose escalation study carmustine . Patients receive O6-benzylguanine IV 1 hour , , 1 hour later , carmustine IV administer 1 hour . Treatment repeat every 6 week 1 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos carmustine maximum tolerate dose ( MTD ) reach . The MTD define dose level few 2 6 patient experience dose limit toxicity ( DLT ) . If myelosuppression DLT , stratum 1 close patient accrue stratum 2 . If neutropenia DLT stratum 2 , patient receive filgrastim ( G-CSF ) subcutaneously begin day 2 continue blood count recover . Patients follow every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven CNS tumor refractory conventional therapy effective therapy know Histological requirement may waive brainstem optic glioma Stratum 2 : No bone marrow involvement PATIENT CHARACTERISTICS : Age : 21 Performance status : Karnofsky 50100 % OR Lansky 50100 % Life expectancy : At least 8 week Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 ( stratum 2 : least 125,000/mm3 ) Hemoglobin least 8 g/dL Bilirubin le 1.5 mg/dL SGOT/SGPT great 2.5 time normal Creatinine GFR normal age If require , DLCO must 80 % normal patient old enough cooperate DLCO test Neurologic deficit must stable least 2 week prior study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : At least 7 day since prior biologic therapy immunotherapy recover At least 6 month since prior bone marrow transplant ( stratum 1 ) At least 7 day since prior growth factor No concurrent filgrastim ( GCSF ) prophylaxis Stratum 2 : No prior bone marrow transplantation At least 2 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea ) recover Stratum 2 : No great 2 prior chemotherapy regimens No prior nitrosourea therapy If receive dexamethasone , must stable decrease dose least 2 week prior study At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 month since prior substantial bone marrow radiation , total body irradiation , hemipelvic radiotherapy , total abdominal/pelvic/chest mantle/Y port radiotherapy Recovered prior radiotherapy Stratum 2 : No prior central axis radiation No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>